Other languages uniQure N.V.

Equities

QURE

NL0010696654

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
4.68 ^USD	+2.41%		+3.08%	-30.87%

Apr. 12	Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	CI
Apr. 02	UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director	Apr. 12
UniQure N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
UniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease	Dec. 19
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	Nov. 29
UniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease	Nov. 29
Worldwide Healthcare Trust net asset value slips in volatile markets	Nov. 23
UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
UniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy Annual Meeting	23-10-24
UniQure N.V. Announces Chief Scientific Officer Changes	23-10-05
UniQure to Cut 114 Jobs as Part of Restructuring Plan to Lower Expenses	23-10-05
UniQure to lay off about 20% of workforce	23-10-05
UniQure Grants Equity Awards to 42 New Employees	23-10-02
UniQure Says FDA Clears Investigational New Drug Application for Mesial Temporal Lobe Epilepsy Therapy	23-09-05
UniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy	23-09-05
UniQure N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01
Insider Sell: Uniqure	23-07-12
UniQure N.V. Announces Executive Changes	23-06-26
UniQure Says its Huntington's Disease Gene Therapy Candidate Showed Potential Clinical Benefit in Phase 1/2 Trial	23-06-21
UniQure Says It Is Set to Receive $100 Million Milestone Payment for First US Commercial Sale of Hemgenix	23-06-20
Sector Update: Health Care Stocks Mostly Lower Late Monday	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages uniQure N.V.

Equities

QURE

NL0010696654

Other languages

Filters